Causes and risk factors of death in patients with thrombotic microangiopathies

Intensive Care Medicine

Volumn 38, Issue 11, 2012, Pages 1810-1817

  Peigne, Vincent ^a   Perez, Pierre ^a   Resche Rigon, Matthieu ^a   Mariotte, Eric ^a   Canet, Emmanuel ^a   Mira, Jean Paul ^a   Coppo, Paul ^a   Veyradier, Agnès ^a   Azoulay, Elie ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Haemostasis disorders; Transfusion

Indexed keywords

CREATININE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER SURVIVOR; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART INFARCTION; HEMOLYSIS; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; PATIENT MONITORING; PLASMAPHERESIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADULT; CASE-CONTROL STUDIES; CAUSE OF DEATH; COMORBIDITY; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMA EXCHANGE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOTIC MICROANGIOPATHIES;

EID: 84868213953     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-012-2638-5     Document Type: Article

References (30)

1. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589-600
2. Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325:398-403
3. George JN, Vesely SK, Terrell DR (2004) The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTPHUS. Semin Hematol 41:60-67
4. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432-1435
5. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585-1594
6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578-1584
7. Veyradier A, Meyer D (2005) Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 3:2420-2427
8. Fujimura Y, Matsumoto M (2010) Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med 49:7-15
9. Malak S, Wolf M, Millot GA, Mariotte E, Veyradier A, Meynard JL, Korach JM, Malot S, Bussel A, Azoulay E, Boulanger E, Galicier L, Devaux E, Eschwège V, Gallien S, Adrie C, Schlemmer B, Rondeau E, Coppo P, des Microangiopathies Thrombotiques (TMA-Rare Diseases Reference Center) (2008) Human immunodeficiency virusassociated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity. Scand J Immunol 68:337-344
10. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393-397
11. Coppo P, Bussel A, Charrier S, Adrie C, Galicier L, Boulanger E, Veyradier A, Leblanc T, Alberti C, Azoulay E, Le Gall JR, Schlemmer B (2003) Highdose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 82:27-38
12. Darmon M, Azoulay E, Thiery G, Ciroldi M, Galicier L, Parquet N, Veyradier A, Le Gall JR, Oksenhendler E, Schlemmer B (2006) Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med 34:2127-2133
13. Zhan H, Streiff MB, King KE, Segal JB (2010) Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. Transfusion 50:868-874
14. Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 127:834-839
15. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Fremeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K (2004) Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 83:233-244
16. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98:1765-1772
17. Brand J (1999) Development, implementation and evaluation of multiple imputation strategies for the statistical analysis of incomplete data sets. Leiden and Erasmus University, Rotterdam
18. van Buuren S, Boshuizen H, Knook D (1999) Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18:681-694
19. Gami AS, Hayman SR, Grande JP, Garovic VD (2005) Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. Am J Med 118:544-547
20. Hawkins BM, Abu-Fadel M, Vesely SK, George JN (2008) Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion 48:382-392
21. Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, Singh P (2009) Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a singlecenter experience. Clin Cardiol 33:213-216
22. Hughes C, McEwan JR, Longair I, Hughes S, Cohen H, Machin S, Scully M (2009) Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost 7:529-536
23. Sane DC, Streer NP, Owen J (2009) Myocardial necrosis in patients with thrombotic thrombocytopenic purpura: pathophysiology and rationale for specific therapy. Eur J Haematol 82:83-92
24. Perez L, Ramappa P, Guzman JA (2008) Myocardial injury in thrombotic thrombocytopenic purpura: a frequent, perplexing complication. Int J Cardiol 128:257-260
25. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, Porta C, Vianelli N, Billio A, Tacconi F, Ascari E (1997) Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 82:429-435
26. Thachil J (2010) The myths about platelet transfusions in immunemediated thrombocytopenias. Br J Haematol 150:494-495
27. Gottschall JL, Pisciotta AV, Darin J, Hussey CV, Aster RH (1981) Thrombotic thrombocytopenic purpura: experience with whole blood exchange transfusion. Semin Thromb Hemost 7:25-32
28. Harkness DR, Byrnes JJ, Lian EC, Williams WD, Hensley GT (1981) Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 246:1931-1933
29. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lammle B, George JN (2009) Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 49:873-887
30. Benhamou Y, Assie C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provôt F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, Rondeau E, Palcoux JB, Mousson C, Vigneau C, Bonmarchand G, Guidet B, Galicier L, Azoulay E, Rottensteiner H, Veyradier A, Coppo P (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica (Epub ahead of print)